Taysha Gene Therapies, Inc. (TSHA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Taysha Gene Therapies, Inc. reported revenue of $9.77M, up 17.3% from the prior year. The company ran a net loss, with a net margin of -1115.3%. It held $343.32M in total assets against $96.38M in total liabilities.
Key ratios (FY2025)
-1130.6%
Operating margin
-1115.3%
Net margin
-44.1%
Return on equity
+17.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $9.77M | $8.33M | $15.45M | $2.50M | — | — | — |
| Operating Income | -$110.50M | -$91.46M | -$72.44M | -$162.45M | -$173.27M | -$43.00M | — |
| Net Income | -$109.00M | -$89.30M | -$111.57M | -$166.01M | -$174.52M | -$60.01M | — |
| EPS (Diluted) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | — | — |
| Total Assets | $343.32M | $160.36M | $172.73M | $126.28M | $213.96M | $258.88M | $15.0K |
| Total Liabilities | $96.38M | $88.84M | $97.79M | $125.33M | $118.57M | $7.58M | $150.0K |
| Shareholders' Equity | $246.94M | $71.53M | $74.94M | $949.0K | $95.38M | $251.30M | -$135.0K |
| Cash & Equivalents | $319.77M | $139.04M | $143.94M | $87.88M | $149.10M | $251.25M | — |
| Operating Cash Flow | -$93.09M | -$81.22M | -$73.02M | -$88.39M | -$117.04M | -$30.73M | — |
| Capital Expenditures | $738.0K | $374.0K | $3.87M | $20.62M | $15.30M | $82.0K | — |
| Shares Outstanding | 285.05M | 204.94M | 186.96M | 63.21M | 38.47M | 37.76M | 10.89M |